Welcome to our dedicated page for Palvella Therapeutics news (Ticker: PVLA), a resource for investors and traders seeking the latest updates and insights on Palvella Therapeutics stock.
Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company developing investigational topical therapies for serious, rare skin diseases and vascular malformations that currently have no FDA-approved treatments. News about Palvella often centers on progress across its QTORIN™ platform, including clinical trial milestones, regulatory designations, and pipeline expansion.
The company’s lead candidate, QTORIN™ 3.9% rapamycin anhydrous gel, is being studied in the Phase 3 SELVA trial for microcystic lymphatic malformations and in the Phase 2 TOIVA trial for cutaneous venous malformations, with additional development planned in clinically significant angiokeratomas. Updates on these programs include topline clinical results, details on trial design, and commentary from investigators and company leadership on efficacy and safety findings.
Palvella also reports news on its second product candidate, QTORIN™ pitavastatin, for disseminated superficial actinic porokeratosis, including announcements of its selection as a new QTORIN-derived therapy and plans for Phase 2 clinical evaluation. Regulatory and grant-related news, such as FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations and Orphan Products Grant funding, provide additional context on how regulators view the unmet need in the company’s target indications.
Investors and observers following PVLA news can expect coverage of quarterly financial results, corporate updates, leadership appointments in areas like medical affairs and innovation, and participation in healthcare conferences. This news stream helps track how Palvella advances its investigational programs, manages its development priorities, and positions its QTORIN™ platform within the rare dermatologic disease landscape, while consistently noting that its product candidates remain investigational and unapproved.
Palvella Therapeutics (Nasdaq: PVLA) announced issuance of U.S. Patent No. 12,636,273, exclusively licensed from Yale, covering topical HMG-CoA reductase inhibitors, including pitavastatin, for porokeratosis, including DSAP, with protection into 2043.
The patent strengthens IP around investigational therapy QTORIN™ pitavastatin, which targets the mevalonate pathway in affected skin. Palvella also has a pending application for its QTORIN-derived formulations and plans a Phase 2 DSAP trial in H2 2026.
Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharma company focused on rare skin diseases and vascular malformations with no FDA-approved therapies, was named Healthcare & Life Sciences Company of the Year at the 2026 PACT Ecosystem Awards.
The award recognizes innovation, clinical and commercial progress, capital formation, and commitment to the Greater Philadelphia life sciences community.
Palvella Therapeutics (Nasdaq: PVLA) reported new data from Phase 3 SELVA and Phase 2 TOIVA trials of QTORIN™ rapamycin for microcystic lymphatic malformations and cutaneous venous malformations.
SELVA showed high responder rates, strong patient satisfaction, and 48% of maximum possible improvement, while TOIVA demonstrated significant, durable lesion reductions. Palvella targets an NDA in 2H 2026.
Palvella Therapeutics (Nasdaq: PVLA) reported new Phase 2 TOIVA data for topical QTORIN™ rapamycin in cutaneous venous malformations (VMs), presented at the 83rd Society for Investigative Dermatology meeting.
Among patients with baseline bleeding (n=4), cVM-IGA Bleeding improved by +2.5 points (p=0.003) and 100% were "satisfied" or "very satisfied" with treatment at Week 12. Baseline qualitative interviews highlighted substantial physical, functional, and psychosocial burden. Palvella notes QTORIN rapamycin could potentially become the first FDA-approved therapy for an estimated 75,000+ U.S. patients with cutaneous VMs.
Palvella Therapeutics (Nasdaq: PVLA) received approval to transfer its common stock listing from the Nasdaq Capital Market to the Nasdaq Global Market, effective at the opening of trading on May 13, 2026.
The move reflects satisfaction of the Global Market’s higher listing standards. Shares will continue trading under the PVLA ticker, and no action is required from existing shareholders.
Palvella Therapeutics (Nasdaq: PVLA) reported Q1 2026 results and a corporate update highlighting clinical progress and strengthened liquidity. Key items: FDA pre-NDA meeting granted for QTORIN rapamycin in microcystic lymphatic malformations (meeting expected Q2 2026) with NDA submission on track for H2 2026.
Company completed an upsized $230.0 million equity financing and held $261.9 million cash and short-term investments as of March 31, 2026. Multiple trials and presentations scheduled through 2027; European patent issued covering compositions through 2038.
Palvella Therapeutics (Nasdaq: PVLA) announced dosing of first patients in the Phase 2 LOTU trial of QTORIN™ 3.9% rapamycin anhydrous gel for clinically significant angiokeratomas. The single-arm, baseline-controlled study will enroll up to 15 subjects (ages ≥6) at U.S. centers. Topline results are expected in the second half of 2027. QTORIN™ has FDA Fast Track designation and is formulated to target dermal mTOR-driven disease while minimizing systemic exposure. The study measures safety, tolerability, and multiple efficacy endpoints through Week 12.
Palvella Therapeutics (Nasdaq: PVLA) will report first quarter 2026 financial results before market open on Thursday, May 7, 2026. Management will host a conference call and webcast at 8:30 a.m. ET the same day to discuss results and provide a corporate update.
Investors can join the live webcast via the company’s Events & Presentations page or dial in at 800-715-9871 (domestic) or +1 646-307-1963 (international) using Conference ID 9970701. A replay will be archived for 90 days.
Palvella Therapeutics (Nasdaq: PVLA) announced that two late-breaking abstracts reporting results from the Phase 3 SELVA and Phase 2 TOIVA studies of QTORIN™ 3.9% rapamycin anhydrous gel were accepted for presentation at the ISSVA World Congress 2026.
Findings cited include statistically significant, clinically meaningful improvement in microcystic lymphatic malformations (SELVA) and cutaneous venous malformations (TOIVA). The presentations will occur during the late-breaking session on May 20, 2026 at 4:30 p.m. ET, presented by James Treat, MD. Slides will be available at the company website at the session start.
Palvella Therapeutics (Nasdaq: PVLA) appointed John D. Doux, M.D., M.B.A., to its Board of Directors effective April 13, 2026. Dr. Doux is a board-certified dermatologist, investor, and former Palvella director (2019–2022) with deep rare-skin-disease expertise and prior healthcare investment experience.
His background includes a 2015 Journal of Investigative Dermatology editorial advocating orphan-disease models in dermatology, roles at Palo Alto Investors since 2004, and board service at patient groups and biotech companies.